Jubilant Life, Cipla rally up to 6% on inking pact with Gilead Sciences
According to the statements issued by Jubilant Life and Cipla, both the firms will have the right to register, manufacture and sell Gilead's Remdesivir drug in 127 countries including India
No comments:
Post a Comment